In view of the economic environment, Novozymes considers its current 2009 growth outlook satisfactory. The slowdown in 4Q 2008 is not considered a reliable indicator of 2009 full-year performance. Sales growth is forecast at 8-13% (in terms of DKR), and operating profit is expected to grow by 10-15%
โฆ LIBER โฆ
Verenium reports financial results for the 4Q and year ended Dec 2011
- Book ID
- 114373616
- Publisher
- Elsevier Science
- Year
- 2012
- Weight
- 47 KB
- Volume
- 2012
- Category
- Article
- ISSN
- 1351-4180
No coin nor oath required. For personal study only.
๐ SIMILAR VOLUMES
Verenium Corp reports financial results
๐
Article
๐
2009
๐
Elsevier Science
โ 59 KB
Verenium reports financial results for t
๐
Article
๐
2010
๐
Elsevier Science
โ 61 KB
Verenium reports financial results for t
๐
Article
๐
2011
๐
Elsevier Science
โ 55 KB
Verenium reports financial results for 3
๐
Article
๐
2013
๐
Elsevier Science
โ 47 KB
Verenium reports financial results for t
๐
Article
๐
2008
๐
Elsevier Science
โ 52 KB
Verenium reports financial results for t
๐
Article
๐
2010
๐
Elsevier Science
โ 52 KB
## Umicore 1H 2010 For its 1H 2010, Umicore has reported revenues of โฌ987.1 M (โฌ860.2 M for its 1H 2009), recurring EBIT of โฌ186.3 M (โฌ49.5 M), EBITDA of โฌ244.3 M (โฌ111.6 M), basic EPS of โฌ1.24 (โฌ0.18), R&D expenditure of โฌ66.2 M (6% of revenues), and capital expenditure of โฌ75.5 M. An interim div